Ask AI
ProCE Banner Activity

CheckMate 577: Final OS Analysis of Adjuvant Nivolumab vs Placebo in Resected Esophageal or Gastroesophageal Junction Cancer After Neoadjuvant Chemoradiotherapy

Conference Coverage
Slideset

The final OS analysis from phase III CheckMate 577 trial demonstrated a clinically meaningful, although not statistically significant, improvement in OS with adjuvant nivolumab vs placebo with sustained DFS and DMFS benefits in patients with EC or GEJC and residual disease after neoadjuvant CRT and resection.

Released: June 05, 2025

Expiration: December 04, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from Daiichi Sankyo, Inc. and Genentech, a member of the Roche Group.

Daiichi Sankyo, Inc.

Genentech, a member of the Roche Group